2026
- Follow the Money · Clinical5 min read
Nonprofit hospitals are selling longevity packages from $5,500. Here is what in them is free.
STAT published the first part today of a series on a trend we have watched arrive: cash-pay longevity clinics inside nonprofit academic hospitals, naming Northwestern, Weill Cornell and the Mayo Clinic.
- Real Food · Clinical4 min read
Texas wrote its own dietary guidelines today. Six lines, one sentence we'd keep, and a rule for medical schools.
The Texas Nutrition Advisory Committee, created by a 2025 state law, published the first Dietary Guidelines for Texans today. There are six: fill half your plate with vegetables and fruit; eat three or more servings of healthy proteins a day; include healthy fats; eat foods for…
- Sleep · Clinical4 min read
GLP-1 drugs help sleep apnea. The machine still beats them, and most people won't wear it.
A review published today in JAMA Otolaryngology–Head & Neck Surgery does the sorting that sleep-apnea patients have needed since tirzepatide was approved for the condition in December 2024.
- Mouse Dish or Human?4 min read
Mouse, dish or human? Semaglutide extended lifespan in old female mice by 92 days.
A paper in Nature today, with a same-day release from the National Institutes of Health, reports that semaglutide — the molecule in Wegovy — given to female mice from 20 months of age extended their median lifespan from 742 days to 834, about 12%.
- Sleep · Evidence4 min read
A sleep drug was approved today on trial data. Note what the sleep aisle has never had to show.
The FDA approved oveporexton today, the first drug that works by switching on the brain's orexin system — the wakefulness signal that is missing in people with narcolepsy type 1, a condition affecting an estimated 120,000 Americans.
- Evidence · Clinical4 min read
The first person has been dosed with a reprogramming therapy. Phase 1 means safety, not benefit.
Life Biosciences announced today that the first participant has been dosed in the Phase 1 trial of ER-100, the partial epigenetic reprogramming therapy whose trial clearance we covered in January.
- Follow the Money · Clinical4 min read
The FDA warned 30 telehealth companies about GLP-1 ads. The word at issue is 'same.'
The FDA announced today that it has sent warning letters to 30 telehealth companies over the marketing of compounded GLP-1 drugs — versions of semaglutide and tirzepatide made by compounding pharmacies rather than the manufacturers.
- Follow the Money · Clinical4 min read
A prescription drug now costs what a longevity subscription does. Compare what you get.
The pill version of Wegovy, approved two weeks ago, went on sale today at more than 70,000 US pharmacies, including CVS and Costco, and through telehealth companies.
2025
- Clinical · Evidence4 min read
A weight-loss pill with trial data. The longevity aisle should take notes.
The FDA approved today a once-daily pill form of semaglutide, the GLP-1 drug sold as Wegovy, for chronic weight management. In the trial that supported it, 307 adults took the pill or a placebo for 64 weeks; those on the drug lost on average 13.6% of body weight against 2.4% on…
- Clinical · Sex Differences4 min read
The black box came off hormone therapy today. A 22-year label, built on 63-year-old participants.
The FDA announced today that it will remove the boxed warnings on menopausal hormone therapies for cardiovascular disease, breast cancer and probable dementia.
- Real Food · Clinical4 min read
Doctors get about 19 hours of nutrition training. Patients get podcasts.
The Department of Health and Human Services and the Department of Education asked medical schools today to strengthen nutrition education across pre-med, medical school and residency, and to report their commitments within two weeks.
- Clinical · Sex Differences4 min read
An FDA panel wants the scariest warning on hormone therapy gone. The 2002 study behind it was about different women.
An expert panel convened by the FDA commissioner urged the agency today to remove the boxed warning — the agency's most severe label — from menopausal hormone therapies, beginning with low-dose vaginal estrogen.